
FORM D

Notice of Exempt Offering of Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.



1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	Vone None	Entity Type
0001372514			Corporation
Name of Issuer			C Limited Partnership
EYEGATE PHARMACEUTICALS INC			C Limited Liability Company
Jurisdiction of Incorporation/Organization			C General Partnership
DELAWARE			C Business Trust
Year of Incorporation/Organizat	ion		C Other
• Over Five Years Ago			
C Within Last Five Years (Specify Year)			

• Yet to Be Formed

2. Principal Place of Business and Contact Information Name of Issuer EYEGATE PHARMACEUTICALS INC Street Address 1 Street Address 2 [271 WAVERLEY OAKS ROAD, SUITE 108 City State/Province/Country ZIP/Postal Code Phone No. of Issuer [WALTHAM] [02452]


3. Related Persons

Last Name		First Name			Middle Name		
Strem		Brian					
Street Address 1			s	treet Address 2	1		
271 Waverley Oaks Roa	d, Suite 1	08	[
City		State/Province/0	Count	ry	ZIP/Postal Code		
Waltham		MASSACHUS	SETT	8	02452		
Relationship:	Execut	ive Officer	•	Director	Promoter		
Clarification of Response (if	Necessary)					
President and Chief Execut	tive Office	r					
Last Name		First Name			Middle Name		
Romano							
Street Address 1			s	treet Address 2	-		
271 Waverley Oaks Roa	d, Suite 1	08	[
City		State/Province/0	Count	ry	ZIP/Postal Code		
Waltham		MASSACHUS	SETT	s	02452		

Relationship:		Execut	ive Officer	Π	Director		Π	Promoter
					_			
Clarification of Response	e (if N	ecessary)					
Chief Financial Officer								
Last Name			First Name			Middle	Name	
From			Stephen]		
Street Address 1				s	treet Address 2	_		
271 Waverley Oaks H	Road,	Suite 1)8	[
City			State/Province/	Coun	try	ZIP/Pos	stal Co	ode
Waltham			MASSACHU	SETT	s	02452		
Relationship:		Execut	ive Officer	•	Director			Promoter
Clarification of Response	o (if N	00055317)				·	- <u> </u>
Clarification of Response	, (H 1)	ccosary	1					
Last Name			First Name			Middle	Name	•
Chaney]	Paul]		
Street Address 1			<u>[</u>	s	treet Address 2	1		
271 Waverley Oaks H	heoS	Suite 10	18	Ī]
City	toau,	Suite IV	State/Province/	[] Count		ZIP/Pos	tal C	ada
Waltham]	I			02452		
wattham			MASSACHU	SETT	3	02432		
Relationship:		Frecut	ive Officer		Director			Promoter
	1			1	Director		1	
Clarification of Response	e (if N	ecessary)					
Last Name]	First Name			Middle	Name	
Shapiro			Aron					
Street Address 1			1	S Tr	treet Address 2			
271 Waverley Oaks I	Road,	Suite 1						
City		1	State/Province/			ZIP/Pos		ode
Waltham			MASSACHU	SETT	S	02452		
	1			1			10.00	·
Relationship:		Execut	ive Officer		Director			Promoter
Clarification of Response	e (if N	ecessary)					
Last Name			First Name			Middle	Name	
Gayron			Kenneth]		
Street Address 1				S	treet Address 2	-		
271 Waverley Oaks Road, Suite 108								
City			State/Province/	<u>ں</u> Count	try	ZIP/Pos	stal Co	ode
Waltham			MASSACHU		-	02452]
<u></u>]	<u> </u>					
	1				_			
Relationship:		Executi	ive Officer		Director			Promoter

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Tyle	Praveen	
[<u>[</u>		
Street Address 1	Street Address	\$ 2
271 Waverley Oaks Road, Suite	108	
City	State/Province/Country	ZIP/Postal Code
Waltham	MASSACHUSETTS	02452
Relationship: Exec	utive Officer Director	Promoter Promoter
Clarification of Response (if Necessa	rv)	
<u>r</u>		
Last Name	First Name	Middle Name
Daniels	Eric	
Street Address 1	Street Address	s 2
271 Waverley Oaks Road, Suite	108	
City	State/Province/Country	ZIP/Postal Code
Waltham	MASSACHUSETTS	02452
Relationship: Exec	utive Officer Director	Promoter
Clarification of Response (if Necessa	ry)	
Chief Development Officer		



C Agriculture

Banking & Financial Services

- C Commercial Banking
- C Insurance
- C Investing
- C Investment Banking
- C Pooled Investment Fund
- Other Banking & Financial C Services

C Business Services

Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation
- C Environmental Services
- C Oil & Gas
- C Other Energy

C Biotechnology

C Health Insurance

Pharmaceuticals

C Other Health Care

Hospitals & Physicians

C

 \odot

C Manufacturing

Real Estate

0

C Commercial

C Construction

C Residential

REITS & Finance

0

C Other Real Estate

- C Retailing C Restaurants
 - Technology
 - C Computers
 - **C** Telecommunications
 - C Other Technology

Travel

- C Airlines & Airports
 - C Lodging & Conventions
 - C Tourism & Travel Services
- C Other Travel
- C Other

5. Issuer Size

Revenue Range

- C No Revenues
- C \$1 - \$1,000,000
- C \$1,000,001 - \$5,000,000
- C \$5,000,001 - \$25,000,000
- \$25,000,001 \$100,000,000 C
- C Over \$100,000,000

Aggregate Net Asset Value Range

- 0 No Aggregate Net Asset Value
 - \$1 \$5,000,000
- C \$5,000,001 - \$25,000,000
- 0 \$25,000,001 - \$50,000,000
- C \$50,000,001 - \$100,000,000
- C Over \$100,000,000

Output Decline to Disclose

C Decline to Disclose


Not Applicable

- C Not Applicable
- 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

0

											
	Rule 504(b)(1) (not (i), (ii) or (iii))		Rule 505								
Π	Rule 504 (b)(1)(i)		Rule 506(b)								
	Rule 504 (b)(1)(ii)		Rule 506(c)								
	Rule 504 (b)(1)(iii)		Securities Act Section 4	4(a)(5)							
			Investment Company Act Section 3(c)								

2021-10-21



☑ New Notice Date of First Sale

First Sale Yet to Occur

☐ Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

C Yes © No

9.	. Type(s) of Securities Offered (select all that apply)								
	Pooled Investment Fund Interests	•	Equity						
\square	Tenant-in-Common Securities	Г	Debt						
	Mineral Property Securities		Option, Warrant or Other Right to Acquire Another Security						
	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)						

10. Business Combination Transaction
Is this offering being made in connection with a business combination for $_{\rm Yes}$ C $_{\rm No}$ transaction, such as a merger, acquisition or exchange offer?
Clarification of Response (if Necessary)
This Form D relates to the issuance of shares of common stock as transaction consideration to the former stockholders of Bayon Therapeutics, Inc.
11. Minimum Investment
Minimum investment accepted from any outside s USD
12. Sales Compensation
Recipient CRD Number 🔲 None
(Associated) Broker or Dealer I None (Associated) Broker or Dealer CRD I None Number None

Street Address 1		Street Addr	ress 2		
City		State/Province/Co	untry	ZIP/Pos	stal Code
State(s) of Solicitation	1	□ All States			
13 Offering	and Sales Amoun	ts			
Total Offering Amoun	ıt \$	USD 🔽 In	definite		
Total Amount Sold	\$ 67258	USD			
Fotal Remaining to be Sold	\$	USD 🔽 In	definite		
Clarification of Respo	nse (If Necessary) nmon stock were issued on	October 21 2021			
with the value abov	e based on the closing price ay be issuable upon potent	on such date.	,		
	aggregate value of up to app				
14. Investors					
do not quali	rities in the offering have been fy as accredited investors, uch non-accredited investors		-		
to persons w	of whether securities in the off ho do not qualify as accredite avestors who already have inv	d investors, enter t	he total	6	
15. Sales Co	mmissions & Find	lers' Fees E	Expenses	5	
	e amounts of sales commission wn, provide an estimate and c				t of an
-	Commissions \$	1	USD	Estimate	
	Finders' Fees \$ 0		USD	Estimate	
Clasification of Demo]			
Clarification of Respo	nse (if Necessary)				
]
16. Use of Pi	oceeds				
any of the persons req	f the gross proceeds of the offe uired to be named as executiv own, provide an estimate and	e officers, directors	s or promoters	in response to	
	\$	0	US	SD 🔽	Estimate
Clarification of Respo	nse (if Necessary)				
<u></u>					
Signature an	d Submission				

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains its principal place of business or any State in which the state in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the state in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
EYEGATE PHARMACEUTICA INC	LS /s/ Sarah Romano	Sarah Romano	Chief Financial Officer	2021-11-04